Professional Documents
Culture Documents
Jocris A. Cabaguan
Page 1
References
Katzung, B. G., Masters, S. B., & Trevor, A. J. (2011) Basic and Clinical Pharmacology. Twelfth Edition. McGraw-Hill Companies, Inc.
Navarra, S. V., Guzman, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., Li, E. K., Thomas, M., Kim, H. Y., Leon, M. G., Tanasescu, C., Nasonov, E., Lan, J. L., Pineda, L., Zhong, Z. J., Freimuth, W., & Petri, M. A. (2011). Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. BLISS-52 Study Group. 26;377(9767):721-31 Jacobi, A. M., Huang, W., Wang, T., Freimuth, W., Sanz, I., Furie, R., Mackay, M., Aranow, C., Diamond, B., & Davidson, A. (2010). Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebocontrolled, dose-ranging study. Arthritis and Rheumatism. 62(1):201-10 Wallace, D. J., Stohl, W., Furie, R. A., Lisse, J. R., McKay, J. D., Merrill, J. T., Petri, M. A., Ginzler, E. M., Chatham, W. W., McCune, W. J., Fernandez, V., Chevrier, M. R., Zhong, Z. J., & Freimuth, W. W. (2009). A phase II, randomized, double-blind, placebocontrolled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis and Rheumatism. 61(9):1168-78 Furie, R., Stohl, W., Ginzler, E. M., Becker, M., Mishra, N., Chatham, W., Merrill, J. T., Weinstein, A., McCune, W. J., Zhong, J., Cai, W., & Freimuth, W. (2008). Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Belimumab Study Group. Arthritis Research and Therapy. 10(5):R109.
Jocris A. Cabaguan
Page 2